Thank you for subscribing!
Finfeed Archived May 17, 2017
On May 12, global pharmaceutical group and leading drug developer, AstraZeneca (LON: AZN) announced positive top-line results for the Phase III PACIFIC trial as Imfinzi demonstrated superior progression-free survival (PFS) in ‘all-comer’ patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC), making it the first immuno-oncology medicine to show superior PFS in this setting. The
Finfeed Archived Apr 05, 2017
BARD1 Life Sciences (ASX: BD1) announced on Tuesday that it had entered into a collaboration agreement with the Institute for Respiratory Health (IRH) in order to evaluate the company’s cancer vaccine.
Next Investors Archived Apr 04, 2017
If you are going to beat cancer, your best bet is to catch it early. Of course, that’s easier said than done. By the time the symptoms of many cancers are apparent, a patient is often already in late stages of the disease. This is particularly true for lung cancer.
Finfeed Archived Mar 30, 2017
With one in every two Australians expected to be diagnosed with cancer by age 85, that accounts for about 3 out of every 10 people who will pass away. Looking globally, WHO reported 14.1 million new cases of cancer worldwide in 2012. How to solve the problem? It’s an age-old question that seems to have
Get expert stock analysis direct in your inbox
Next Investors Archived Mar 16, 2017
One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease. To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures. One $30 million capped ASX junior may have a unique solution.
Finfeed Archived Feb 01, 2017
CDY announced that the US Patent and Trademark Office issued Notice of Allowance for the patent its midkine or MK alopecia patent.
Next Investors Archived Jan 24, 2017
Volume is a key word for life sciences play Cellmid (ASX: CDY). Its key hair loss product Evolis® aims to replace thinning hair with voluminous locks, while management seeks to volumise revenues, stock liquidity, and ultimately shareholders’ returns.
Finfeed Archived Nov 18, 2016
“We wanted advisors who will be active participants in the development of NOX66, including running some of our clinical studies, and not just advising from a distance”.
Finfeed Archived Oct 26, 2016
Noxopharm (ASX:NOX) plans to cut the ribbon on its inaugural clinical study of experimental anti-cancer product, NOX66 in December 2016.
Next Investors Archived Oct 26, 2016
Earlier this month, actor and director Ben Stiller publicised the fact he fought (and beat) an aggressive form of prostate cancer in 2014. He states his success over the oft-deadly disease is down to a PSA test that he took at an earlier age than what doctors commonly recommend.
Finfeed Archived Oct 06, 2016
Shares in Cellmid (ASX: CDY) were up approximately 30% at one stage on Wednesday after the company released promising results regarding the preclinical collaborative trials being undertaken in relation to its anti-midkine antibodies (MK antibodies).
Finfeed Archived Aug 24, 2016
Monday’s announcement of Pfizer Inc’s acquisition of NASDAQ listed Medivation for $14 billion created plenty of attention in the health and biotech space.
Finfeed Archived Aug 22, 2016
Noxopharm (ASX:NOX) will move into radiotherapy in addition to chemotherapy – a move CEO Graham Kelly calls an “extraordinary and unique market opportunity”.
Finfeed Archived Aug 10, 2016
Noxopharm (ASX:NOX) has confirmed it is on track to start clinical trials of its lead cancer drug, NOX66, in Europe by the end of the year.
Next Investors Archived Aug 09, 2016
The weird and wonderful world of Biotechnology has a lot going for it — an industry working at the sharp-end of breakthrough medical research, Biotech is also one of the more enticing investment landscapes of modern times. In how many other industries are companies literally striving to save lives?
Next Investors Archived Jul 19, 2016
One of the latest stocks to list on the ASX happens to have a very small market cap, but a very advanced oncology drug with early sales potential. This $15M capped stock just raised $4M as part of its entry to the ASX, and its inherent value is in a niche cancer drug named Bisantrene that was ‘lost’ in the 1990s – buried under the weight of so-called billion-dollar blockbuster drugs that better suit Big Pharma’s margins.
Next Investors Archived Jun 23, 2016
This ASX micro cap stock has not just one but three potentially winning plays. The company, with a market cap of under $1.5M, has interests in two biotech entities, and also has a stake in a high potential offshore oil and gas play with a key exploration event on the horizon.
Next Investors Archived Jun 14, 2016
With a total global market of $90 billion, successful hair loss products can generate hundreds of millions of dollars in revenue. However the current market leaders may soon be under pressure from one particular ASX listed life sciences company.
Join Our Mailing List
